DK3268385T3 - Kombineret T-cellereceptor-genterapi af cancer mod MHC I og MHC II-begrænsede epitoper af tumorantigenet NY-ESO-1 - Google Patents
Kombineret T-cellereceptor-genterapi af cancer mod MHC I og MHC II-begrænsede epitoper af tumorantigenet NY-ESO-1 Download PDFInfo
- Publication number
- DK3268385T3 DK3268385T3 DK16712262.1T DK16712262T DK3268385T3 DK 3268385 T3 DK3268385 T3 DK 3268385T3 DK 16712262 T DK16712262 T DK 16712262T DK 3268385 T3 DK3268385 T3 DK 3268385T3
- Authority
- DK
- Denmark
- Prior art keywords
- mhc
- eso
- combined
- gene therapy
- cell receptor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 title 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 title 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15159001.5A EP3067366A1 (en) | 2015-03-13 | 2015-03-13 | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
| PCT/EP2016/055242 WO2016146505A1 (en) | 2015-03-13 | 2016-03-11 | Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3268385T3 true DK3268385T3 (da) | 2020-04-06 |
Family
ID=52669528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16712262.1T DK3268385T3 (da) | 2015-03-13 | 2016-03-11 | Kombineret T-cellereceptor-genterapi af cancer mod MHC I og MHC II-begrænsede epitoper af tumorantigenet NY-ESO-1 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10781243B2 (https=) |
| EP (3) | EP3067366A1 (https=) |
| JP (2) | JP6998211B2 (https=) |
| CN (2) | CN114195883A (https=) |
| AU (1) | AU2016232441B2 (https=) |
| CA (1) | CA2974955A1 (https=) |
| DK (1) | DK3268385T3 (https=) |
| ES (1) | ES2784315T3 (https=) |
| HU (1) | HUE049444T2 (https=) |
| PL (1) | PL3268385T3 (https=) |
| PT (1) | PT3268385T (https=) |
| SI (1) | SI3268385T1 (https=) |
| WO (1) | WO2016146505A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| AU2014343379B2 (en) | 2013-11-04 | 2019-02-14 | Uti Limited Partnership | Methods and compositions for sustained immunotherapy |
| EP3291832B1 (en) | 2015-05-06 | 2025-09-03 | UTI Limited Partnership | Nanoparticle compositions for sustained therapy |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP3354658A1 (en) * | 2017-01-25 | 2018-08-01 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases |
| US11236145B2 (en) | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| WO2018185564A2 (en) * | 2017-04-07 | 2018-10-11 | Uti Limited Partnership | Assay to measure the potency of receptor-ligand interactions in nanomedicines |
| CN109837245A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种tcr敲除的靶向ny-eso-1的t细胞受体基因修饰t细胞及其制备方法和应用 |
| CA3083748A1 (en) | 2017-11-29 | 2019-06-06 | Uti Limited Partnership | Methods of treating autoimmune disease |
| TWI822726B (zh) * | 2018-02-26 | 2023-11-21 | 德商梅迪基因免疫治療公司 | Ｎｙｅｓｏ ｔ細胞受體 |
| CN110856751B (zh) | 2018-08-24 | 2024-12-03 | 杭州康万达医药科技有限公司 | 包含核酸及tcr修饰的免疫细胞的治疗剂及其应用 |
| EP3935175A4 (en) | 2019-03-04 | 2023-01-04 | University Health Network | T-LYMPHOCYTE RECEPTORS AND METHODS OF USE THEREOF |
| EP3760217A1 (en) | 2019-07-01 | 2021-01-06 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd5 specific t cell receptor cell or gene therapy |
| US20220273714A1 (en) * | 2019-07-19 | 2022-09-01 | The Regents Of The University Of California | T-cell receptors and methods of use thereof |
| CN112390875B (zh) * | 2019-08-16 | 2023-01-24 | 香雪生命科学技术（广东）有限公司 | 一种识别afp的高亲和力t细胞受体 |
| CN113512124A (zh) * | 2020-04-10 | 2021-10-19 | 香雪生命科学技术（广东）有限公司 | 一种识别hpv16的高亲和力tcr |
| CN112501269B (zh) * | 2020-12-15 | 2022-02-18 | 清华大学 | 一种快速鉴定高亲和力tcr抗原交叉反应活性的方法 |
| CN114121142B (zh) * | 2021-09-02 | 2023-10-31 | 四川大学华西医院 | 一种新型基因修饰增强型ny-eso-1特异型tcr-t模型构建方法及应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000060055A1 (en) * | 1999-04-01 | 2000-10-12 | The Brigham And Women's Hospital, Inc. | Modified dendritic cells and uses therefor |
| WO2001055393A2 (en) * | 2000-01-28 | 2001-08-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1 |
| ES2389251T3 (es) * | 2000-12-19 | 2012-10-24 | Altor Bioscience Corporation | Animales transgénicos que comprenden un sistema inmunitario humanizado |
| AU2003217384A1 (en) * | 2002-02-13 | 2003-09-04 | Ludwig Institute For Cancer Research | Isolated peptides which bind to hla molecules and uses thereof |
| GB0411123D0 (en) * | 2004-05-19 | 2004-06-23 | Avidex Ltd | High-affinity NY-ESO T cell receptors |
| WO2006031221A1 (en) * | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| KR101773690B1 (ko) * | 2007-03-05 | 2017-08-31 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
| CN101381402B (zh) * | 2008-10-20 | 2011-06-01 | 中国人民解放军第三军医大学 | Ny-eso-1肿瘤抗原模拟表位及其应用 |
| HRP20171164T1 (hr) | 2010-09-20 | 2017-10-20 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t stanični receptori i t stanični epitopi |
| EP2852613B1 (en) * | 2012-05-22 | 2019-01-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Murine anti-ny-eso-1 t cell receptors |
| CA2899679C (en) | 2013-01-29 | 2023-03-21 | Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Berlin-Buch | High avidity antigen recognizing constructs |
| RU2578009C2 (ru) * | 2013-05-08 | 2016-03-20 | Закрытое акционерное общество "ЕВРОГЕН" | Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках |
| US11203783B2 (en) * | 2013-11-21 | 2021-12-21 | Repertoire Genesis Incorporation | T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis |
-
2015
- 2015-03-13 EP EP15159001.5A patent/EP3067366A1/en not_active Withdrawn
-
2016
- 2016-03-11 CN CN202111497633.4A patent/CN114195883A/zh active Pending
- 2016-03-11 ES ES16712262T patent/ES2784315T3/es active Active
- 2016-03-11 HU HUE16712262A patent/HUE049444T2/hu unknown
- 2016-03-11 AU AU2016232441A patent/AU2016232441B2/en active Active
- 2016-03-11 SI SI201630678T patent/SI3268385T1/sl unknown
- 2016-03-11 JP JP2017548167A patent/JP6998211B2/ja active Active
- 2016-03-11 US US15/558,021 patent/US10781243B2/en active Active
- 2016-03-11 DK DK16712262.1T patent/DK3268385T3/da active
- 2016-03-11 CA CA2974955A patent/CA2974955A1/en active Pending
- 2016-03-11 WO PCT/EP2016/055242 patent/WO2016146505A1/en not_active Ceased
- 2016-03-11 CN CN201680015622.9A patent/CN107428816B/zh active Active
- 2016-03-11 EP EP20150462.8A patent/EP3666793A3/en active Pending
- 2016-03-11 EP EP16712262.1A patent/EP3268385B1/en active Active
- 2016-03-11 PL PL16712262T patent/PL3268385T3/pl unknown
- 2016-03-11 PT PT167122621T patent/PT3268385T/pt unknown
-
2021
- 2021-06-15 JP JP2021099266A patent/JP2021151249A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016232441A1 (en) | 2017-08-10 |
| AU2016232441B2 (en) | 2020-08-27 |
| EP3268385A1 (en) | 2018-01-17 |
| EP3666793A3 (en) | 2020-07-29 |
| SI3268385T1 (sl) | 2020-07-31 |
| WO2016146505A1 (en) | 2016-09-22 |
| EP3268385B1 (en) | 2020-01-08 |
| CN107428816B (zh) | 2022-01-14 |
| CN107428816A (zh) | 2017-12-01 |
| CA2974955A1 (en) | 2016-09-22 |
| PT3268385T (pt) | 2020-04-08 |
| ES2784315T3 (es) | 2020-09-24 |
| EP3666793A2 (en) | 2020-06-17 |
| EP3067366A1 (en) | 2016-09-14 |
| JP2021151249A (ja) | 2021-09-30 |
| HK1247212A1 (en) | 2018-09-21 |
| US10781243B2 (en) | 2020-09-22 |
| JP6998211B2 (ja) | 2022-02-04 |
| PL3268385T3 (pl) | 2020-06-29 |
| JP2018509163A (ja) | 2018-04-05 |
| HUE049444T2 (hu) | 2020-09-28 |
| US20180057560A1 (en) | 2018-03-01 |
| CN114195883A (zh) | 2022-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3268385T3 (da) | Kombineret T-cellereceptor-genterapi af cancer mod MHC I og MHC II-begrænsede epitoper af tumorantigenet NY-ESO-1 | |
| IL297418B1 (en) | Combination immune therapy and cytokine control therapy for cancer treatment | |
| IL254214A0 (en) | Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer | |
| IL255280A0 (en) | Secretory tnt car cell immunotherapy | |
| EP3548048A4 (en) | CANCER IMMUNOTHERAPY WITH CD8 + HIGHLY ENRICHED CHIMERIC ANTIGEN RECEPTOR T CELLS | |
| IL250043A0 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| IL260342A (en) | Urea-based prostate membrane-specific antigen suppressor for imaging and therapy | |
| IL261422A (en) | Therapeutic and diagnostic methods for cancer | |
| DK3142689T3 (da) | Kombinationsbehandling til behandling af cancer med en koppevirus, som udtrykker et tumorantigen, og et monoklonalt antistof mod tim-3 | |
| IL255312A0 (en) | Therapeutic and diagnostic methods for cancer | |
| DK4095130T3 (da) | Mærkede hæmmere af prostataspecifikt membranantigen (psma), deres anvendelse som billeddannelsesmidler og farmaceutiske midler til behandling af prostatacancer | |
| IL251525A0 (en) | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof | |
| IL282531A (en) | Anti-liv1 immune cell cancer therapy | |
| DK3142751T3 (da) | Anti-B7-H1- og anti-CTLA-4-antistoffer til behandling af ikke-småcellet lungecancer | |
| DK3065770T3 (da) | Kombinationsterapi til behandling af cancer med et poxvirus, der udtrykker et tumorantigen og en antagonist af en immuncheckpoint-inhibitor | |
| DK3151921T3 (da) | Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf | |
| DK3508502T3 (da) | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer | |
| IL258378A (en) | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer | |
| IL262208A (en) | Diagnostic and therapeutic methods for cancer | |
| IL269629A (en) | Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells | |
| PL3622953T3 (pl) | Leczenie skojarzone nowotworu | |
| DK3768830T5 (da) | Cancerterapi | |
| EP3413927A4 (en) | CANCER THERAPY | |
| IL289205A (en) | Novel cancer antigens and methods | |
| DK3362569T3 (da) | Cxcr6-transducerede t-celler til målrettet tumorterapi |